会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明公开
    • 테트라미졸을 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
    • 用于预防或治疗包含TETRAMIZOLE的肌肉脆弱性疾病的药物组合物
    • KR1020140054809A
    • 2014-05-09
    • KR1020120120760
    • 2012-10-29
    • 한국생명공학연구원
    • 박성섭권기선이광표하종성성혜영이승민
    • A61K31/4164C07D233/32C07D233/34A61P21/00
    • A61K31/4188A23L29/045A23L29/055A61K33/20A61K2300/00
    • The present invention relates to a differentiation stimulating composition for a myoblast comprising tetramisole or chloride thereof permitted for pharmaceutical uses; a differentiation stimulating method comprising a step where tetramisole or chloride thereof permitted for pharmaceutical uses is applied on myoblast outside the body; a differentiated myoblast production method which differentiates the myoblast by applying tetramisole or chloride thereof permitted for pharmaceutical uses on the myoblast outside the body; a pharmaceutical composition for preventing or treating muscle weakening diseases comprising tetramisole or chloride thereof permitted for pharmaceutical uses; and a food composition for preventing or improving muscle weakening diseases. The tetramisole according to the present invention stimulates differentiation of the myoblast to create roots, thereby preventing muscular weakening and effectively enhancing muscular functions. Thus, a pharmaceutical composition comprising tetramisole can be usefully applied for preventing or treating muscle weakening diseases.
    • 本发明涉及一种用于成肌细胞的分化刺激组合物,其包含允许用于药物用途的四氯甲酚或其氯化物; 一种分化刺激方法,包括将允许用于药物用途的四马来甲酯或其氯化物施用于身体外的成肌细胞的步骤; 一种分化成肌细胞的生产方法,通过将允许用于药物用途的四聚甲酚或其氯化物在体外的成肌细胞上分化成肌细胞; 一种用于预防或治疗肌肉减弱疾病的药物组合物,其包括药物用途所允许的四氯甲酚或其氯化物; 以及用于预防或改善肌肉减弱疾病的食物组合物。 根据本发明的四马来酸刺激成肌细胞的分化以产生根,从而防止肌肉减弱并有效增强肌肉功能。 因此,包含四马来酸的药物组合物可用于预防或治疗肌肉减弱疾病。
    • 8. 发明公开
    • A composition for treating acute asthma exacerbation by viral infection
    • 用于通过病毒感染治疗急性哮喘发作的组合物
    • KR20120029760A
    • 2012-03-27
    • KR20100091797
    • 2010-09-17
    • NAT UNIV CHONBUK IND COOP FOUNCHONBUK NAT VNIVERSITY HOSPITAL
    • LEE YONG CHUL
    • A61K31/498A61K31/426A61P11/06
    • A61K31/498A23L29/035A23L29/045A23L29/055A23V2200/314Y10S514/826
    • PURPOSE: A composition for treating acute asthma caused by virus infection is provided to control increase of inflammation cell inside bronchoalveolar lavage fluid and airway resistance. CONSTITUTION: A composition for treating acute asthma caused by virus infection includes AS-605240 as an active ingredient. The acute asthma is induced by processing polyinosinic-polycytidylic acid. The AS-605240 suppresses expression of adhesion, inflammation cell, IgE, Th2, cytokine, chemokine, and vascular endothelial growth factor(VEGF). The composition is formulated in pharmaceutical unit dose form by adding pharmaceutically allowed carrier, excipient, or diluent. The composition is administered in effective amount of 0.1-1mg/kg. A health food for preventing or improving acute asthma caused by virus infection includes AS-605240 as an active ingredient.
    • 目的:提供用于治疗由病毒感染引起的急性哮喘的组合物,以控制支气管肺泡灌洗液内炎症细胞的增加和气道阻力。 构成:用于治疗由病毒感染引起的急性哮喘的组合物包括AS-605240作为活性成分。 急性哮喘是通过加工聚肌苷酸 - 聚胞苷酸诱导的。 AS-605240抑制粘附,炎症细胞,IgE,Th2,细胞因子,趋化因子和血管内皮生长因子(VEGF)的表达。 通过加入药学上允许的载体,赋形剂或稀释剂将组合物配制成药物单位剂量形式。 给药组合物有效量为0.1-1mg / kg。 用于预防或改善由病毒感染引起的急性哮喘的保健食品包括AS-605240作为活性成分。